Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma.
PLK1
mucinous ovarian carcinoma
screening
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
21
02
2020
revised:
02
03
2020
accepted:
11
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Mucinous epithelial ovarian cancer (mEOC) is a rare subset of epithelial ovarian cancer. When diagnosed at a late stage, its prognosis is very poor, as it is quite chemo-resistant. To find new therapeutic options for mEOC, we performed high-throughput screening using a siRNA library directed against human protein kinases in a mEOC cell line, and polo-like kinase1 (PLK1) was identified as the kinase whose downregulation interfered with cell proliferation. Both PLK1 siRNA and two specific PLK1 inhibitors (onvansertib and volasertib) were able to inhibit cell growth, induce apoptosis and block cells in the G2/M phase of the cell cycle. We evaluated,
Identifiants
pubmed: 32183025
pii: cancers12030672
doi: 10.3390/cancers12030672
pmc: PMC7140026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 19797
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Transl Oncol. 2015 Jun;8(3):185-95
pubmed: 26055176
Clin Cancer Res. 2015 Jun 1;21(11):2445-52
pubmed: 25838395
Cancer Res. 2014 Dec 1;74(23):6980-90
pubmed: 25304260
Am J Obstet Gynecol. 2011 Nov;205(5):480.e1-8
pubmed: 21861962
Onco Targets Ther. 2015 Jul 17;8:1761-71
pubmed: 26229484
Cancer Lett. 2018 Dec 28;439:56-65
pubmed: 30243708
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Oncotarget. 2018 May 25;9(40):25842-25859
pubmed: 29899826
Methods Mol Biol. 2016;1470:137-49
pubmed: 27581290
Oncogene. 2005 Jan 10;24(2):267-76
pubmed: 15640842
J Pharmacol Exp Ther. 2015 Mar;352(3):579-89
pubmed: 25576074
Transl Oncol. 2017 Feb;10(1):22-32
pubmed: 27888710
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Mol Cancer Ther. 2019 Jul;18(7):1255-1264
pubmed: 31064869
Invest New Drugs. 2018 Feb;36(1):85-95
pubmed: 28726132
Mol Oncol. 2015 Jan;9(1):140-54
pubmed: 25169932
Int J Oncol. 2016 Mar;48(3):1187-94
pubmed: 26794530
Clin Genet. 2008 Apr;73(4):338-45
pubmed: 18312450
Clin Cancer Res. 2001 Sep;7(9):2912-22
pubmed: 11555610
J Clin Oncol. 2016 Mar 1;34(7):706-13
pubmed: 26755507
Anticancer Res. 2005 Sep-Oct;25(5):3501-5
pubmed: 16101169
Br J Cancer. 2004 Feb 23;90(4):815-21
pubmed: 14970859
Mol Cancer Ther. 2012 Apr;11(4):1006-16
pubmed: 22319201
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57
pubmed: 27141073
Cell Death Differ. 2015 Dec;22(12):1946-56
pubmed: 26024389
Cell Cycle. 2012 Jul 1;11(13):2507-17
pubmed: 22713237
Methods Mol Biol. 2013;986:89-95
pubmed: 23436407
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29795040
Crit Rev Oncol Hematol. 2016 Jun;102:26-36
pubmed: 27083591
Cancer Lett. 2001 Mar 10;164(1):41-9
pubmed: 11166914
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Clin Oncol. 2004 Mar 15;22(6):1040-4
pubmed: 15020606
Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40
pubmed: 15173822
Leukemia. 2015 Jan;29(1):11-9
pubmed: 25027517
Genome Med. 2017 Jan 12;9(1):1
pubmed: 28081715
J Natl Cancer Inst. 2002 Dec 18;94(24):1863-77
pubmed: 12488480
Gynecol Oncol. 2003 Aug;90(2):378-81
pubmed: 12893203
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
Oncology. 2008;74(3-4):198-206
pubmed: 18714168
Ann Oncol. 2010 Dec;21(12):2377-81
pubmed: 20494964
FASEB J. 2005 Apr;19(6):611-3
pubmed: 15661849
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
Gynecol Oncol. 2009 Jun;113(3):331-4
pubmed: 19275957
J Natl Cancer Inst Monogr. 1993;(15):107-15
pubmed: 7912516
Exp Hematol Oncol. 2012 Dec 10;1(1):38
pubmed: 23227884
Hum Genomics. 2016 Dec 28;10(1):40
pubmed: 28031051
Oncotarget. 2017 Apr 18;8(32):52445-52456
pubmed: 28881742